Stockscreener 앱 받기
36.67
0.22%
0.08
시간 외 거래:
36.75
0.08
+0.22%
전일 마감가:
$36.59
열려 있는:
$36.65
하루 거래량:
1.93M
Relative Volume:
0.50
시가총액:
$15.45B
수익:
$2.26B
순이익/손실:
$1.09B
주가수익비율:
15.65
EPS:
2.3431
순현금흐름:
$2.70B
1주 성능:
+3.03%
1개월 성능:
+2.12%
6개월 성능:
+18.06%
1년 성능:
+27.86%
1일 변동 폭
$36.29
$36.71
1주일 범위
$35.51
$36.71
52주 변동 폭
$24.05
$36.89
로열티 파마 Stock (RPRX) Company Profile
명칭
Royalty Pharma Plc
전화
(212) 883-0200
주소
110 EAST 59TH STREET, NEW YORK, NY
RPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
36.67 | 15.42B | 2.26B | 1.09B | 2.70B | 2.3431 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
로열티 파마 Stock (RPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-16 | 개시 | Morgan Stanley | Overweight |
| 2024-06-03 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-06-14 | 재개 | UBS | Buy |
| 2022-05-13 | 개시 | Scotiabank | Sector Outperform |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2022-04-14 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2021-10-29 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-07-30 | 개시 | Tigress Financial | Buy |
| 2020-11-09 | 업그레이드 | UBS | Neutral → Buy |
| 2020-07-14 | 개시 | Evercore ISI | In-line |
| 2020-07-13 | 개시 | BofA Securities | Buy |
| 2020-07-13 | 개시 | Citigroup | Neutral |
| 2020-07-13 | 개시 | Cowen | Outperform |
| 2020-07-13 | 개시 | Goldman | Neutral |
| 2020-07-13 | 개시 | JP Morgan | Neutral |
| 2020-07-13 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-07-13 | 개시 | SunTrust | Buy |
| 2020-07-13 | 개시 | UBS | Neutral |
모두보기
로열티 파마 주식(RPRX)의 최신 뉴스
Royalty Pharma plc Stock Analysis and ForecastSuperior portfolio returns - PrintWeekIndia
Is Royalty Pharma plc a good long term investmentDouble-digit growth - Autocar Professional
Royalty Pharma PLC (NASDAQ:RPRX) Holdings Lifted by Los Angeles Capital Management LLC - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Shares Sold by New York State Common Retirement Fund - MarketBeat
Royalty Pharma Plc's (NASDAQ:RPRX) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects? - 富途牛牛
Winners And Losers Of Q1: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks - Yahoo Finance
21,158 Shares in Royalty Pharma PLC (NASDAQ:RPRX) Acquired by Edgestream Partners L.P. - MarketBeat
What analysts say about Royalty Pharma plc stockTremendous portfolio expansion - jammulinksnews.com
Vestor Capital LLC Buys New Stake in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
What drives Royalty Pharma plc stock pricePhenomenal wealth increase - Autocar Professional
Citigroup Issues Positive Forecast for Royalty Pharma (NASDAQ:RPRX) Stock Price - MarketBeat
Citigroup maintains Buy rating, raises PT for Royalty Pharma to $42. - AInvest
Citi raises Royalty Pharma stock price target to $42 on CF and Tremfya growth By Investing.com - Investing.com South Africa
Citi raises Royalty Pharma stock price target to $42 on CF and Tremfya growth - Investing.com Nigeria
Royalty Pharma (RPRX) PT Raised to $42 at Citi - StreetInsider
Royalty Pharma PLC to Issue Quarterly Dividend of $0.22 (NASDAQ:RPRX) - MarketBeat
C WorldWide Group Holding A S Acquires New Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma PLC (NASDAQ:RPRX) Stake Raised by Victory Capital Management Inc. - MarketBeat
Morgan Stanley Raises Royalty Pharma (RPRX) Price Target, Maintains Overweight Rating - MSN
Cullen Frost Bankers Inc. Acquires 247,903 Shares of Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Reaches New 52-Week HighTime to Buy? - MarketBeat
Royalty Pharma Declares Q3 2025 Dividend of $0.22 per Class A Share - AInvest
Royalty Pharma Declares Q3 2025 Dividend of $0.22 per Class A Ordinary Share - AInvest
Royalty Pharma Declares Third Quarter 2025 Dividend - The Globe and Mail
Royalty Pharma announces $0.22 per share dividend for Q3 2025 - Investing.com
Royalty Pharma plc (RPRX) Declares $0.22 Quarterly Dividend; 2.5% Yield - StreetInsider
Royalty Pharma Announces Q3 2025 Dividend of $0.22 per Share - AInvest
How to Take Advantage of moves in (RPRX) - news.stocktradersdaily.com
Bryn Mawr Capital Management LLC Boosts Stock Position in Royalty Pharma PLC (NASDAQ:RPRX) - MarketBeat
Is Royalty Pharma plc stock a good hedge against inflationHigh Potential Safe Trades - Newser
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman To Board - citybiz
Royalty Pharma adds two independent directors to board By Investing.com - Investing.com India
로열티 파마 (RPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.97%
0.42%
자본화:
|
볼륨(24시간):